HOME >> BIOLOGY >> NEWS
Switching off Huntington's

USING gene therapy to switch off genes instead of adding new ones could slow down or prevent the fatal brain disorder Huntington's disease. The method, which exploits a mechanism called RNA interference, might also help treat a wide range of other inherited diseases.

"When I first heard of this work, it just took my breath away," says Nancy Wexler of Columbia University Medical School, who is president of the Hereditary Disease Foundation in New York. Though the gene-silencing technique has yet to be tried in people, she says it is the most promising potential treatment so far for Huntington's.

It involves a natural defence mechanism against viruses, in which short pieces of double-stranded RNA (short interfering RNAs, or siRNAs) trigger the degradation of any other RNA in the cell with a matching sequence. If an siRNA is chosen to match the RNA copied from a particular gene, it will stop production of the protein the gene codes for (see Graphic).

Huntington's is caused by mutations in the huntingtin gene. The resulting defective protein forms large clumps that gradually kill off part of the brain. Studies in mice have shown that reducing production of the defective protein can slow down the disease, and Beverly Davidson at the University of Iowa thinks the same could be true in people.

"If you reduce levels of the toxic protein even modestly, we believe you'll have a significant impact," she says. Late last year, her team showed that it is possible to reduce the amount of a similar protein by up to 90 per cent, by adding DNA that codes for an siRNA to rodent cells engineered to produce the protein.

The team was the first to use gene therapy to deliver such a payload, and they have now done the same with the huntingtin protein itself. Completely silencing the gene in people with the disease is not an option because brain cells may not survive without the protein. But we have two copies of most genes, and usually only one is defective in peop
'"/>

Contact: Claire Bowles
claire.bowles@rbi.co.uk
44-207-331-2751
New Scientist
12-Mar-2003


Page: 1 2

Related biology news :

1. Switching on the fly genome
2. World Congress on Huntingtons Disease to meet in Toronto, August 16-19, 2003
3. Link between neuronal calcium channel, mutated gene that causes Huntingtons disease identified
4. Fasting forestalls Huntingtons disease in mice
5. Novel gene mutation causes Huntingtons-like symptoms, providing window into how brain cells die
6. Bile acid inhibits cell death in Huntingtons disease
7. Stanford researchers home in on Huntingtons disease treatment
8. Scientists find solution to a mystery surrounding Alzheimers, Huntingtons and other neurological diseases
9. Using a mouse model, reserchers now understand changes occurring in the brain before the onset of Huntingtons disease
10. Hopkins researchers identify neurologic problem associated with motor disorders in Huntingtons disease
11. Weizmann researchers find evidence that links molecular mechanism to Huntingtons Disease

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/10/2017)... , Feb 10, 2017 Research ... report "Personalized Medicine - Scientific and Commercial Aspects" ... ... medicine. Diagnosis is integrated with therapy for selection of treatment ... early detection and prevention of disease in modern medicine. Biochip/microarray ...
(Date:2/8/2017)... Feb. 7, 2017  Aware, Inc. (NASDAQ: AWRE ... reported financial results for its quarter and year ended December ... of 2016 was $3.9 million compared to $6.9 million in ... quarter of 2016 was $0.6 million compared to $2.6 million ... fourth quarter of 2016 was $0.5 million, or $0.02 per ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... billion by 2021 from $8.3 billion in 2016 at ... 2016 to 2021. Report Includes - An overview ... global market trends, with data from 2015 and 2016, ... 2021. - Segmentation of the market on the basis ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... -- Symic Bio, a biopharmaceutical company focused on matrix ... announced today the completion of enrollment for the SHIELD ... trial will evaluate the safety and efficacy of SB-030, ... restenosis following angioplasty. "We,re pleased to ... Nathan Bachtell , M.D., Chief Medical Officer of ...
(Date:2/24/2017)... ... , ... FireflySci, Inc is an explosive small business that continues to grow ... bringing their powerful cuvette and spectrophotometer calibration to the spectroscopy world. ... on as they add yet another mark on the global map. , With distributors ...
(Date:2/24/2017)... 2017  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a ... Key Opinion Leader event to highlight new clinical data ... presentation at the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium and ... be held in-person and via live webcast on Tuesday, ... PST at the Lotte New York Palace Hotel in ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... portfolio to include an array of biochemical analyses critical for Lead Discovery. ... drive their hit-to-lead and SAR programs, including inhibitor potency and selectivity, mechanism of ...
Breaking Biology Technology:
Cached News: